Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 22 resultados

ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-07 The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare...
2024-08-20 - 2031-08-31 | Financiado

ECOWAS-RegECs: Practical strengthening of regulatory and ethics oversight on clinical trials in West Africa using L... BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un HORIZON EUROPE: HORIZON-JU-GH-EDCTP3-2022-01 The proposed strengthening project for clinical research oversight in ECOWAS region, consists of practical training of regulatory and ethics...
2023-06-01 - 2025-05-31 | Financiado

Inno4Vac: Innovations to accelerate vaccine development and manufacture BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling...
2021-07-19 - 2027-02-28 | Financiado

EuroGCT: European consortium for communicating gene and cell based therapy information. BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-SC1-BHC-2018-2020 The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) unites 49 partner organisations and institutions acros...
2021-01-25 - 2026-01-31 | Financiado

T2EVOLVE: Accelerating Development and Improving Access to CAR and TCR engineered T cell therapy BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative...
2020-11-24 - 2025-12-31 | Financiado

T-OP: Training Network for Optimizing Adoptive T cell Therapy of Cancer BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-MSCA-ITN-2020 Over the last years, immunotherapy – using a patient’s own immune system to fight tumours – has emerged as an important complement to standa...
2020-08-27 - 2025-02-28 | Financiado

EU-PEARL: EU Patient cEntric clinicAl tRial pLatform BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage EU-PEARL has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company I...
2019-11-27 - 2023-04-30 | Financiado

COMBINE: Collaboration for Prevention and Treatment of MDR Bacterial Infections BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The loss of antibiotic effectiveness due to increasing antimicrobial resistance (AMR) is a serious threat to global public health. The IMI2...
2019-11-27 - 2025-10-31 | Financiado

imSAVAR: Immune Safety Avatar nonclinical mimicking of the immune system effects of immunomodulatory therapi... BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy saf...
2019-11-18 - 2025-11-30 | Financiado

TIPAT: Training towards Personalized Antibiotic Treatment BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-MSCA-ITN-2019 Antimicrobial resistance (AMR) is an increasing threat to effectively treat serious bacterial infections. To this end, tailoring antibiotic...
2019-08-12 - 2024-08-31 | Financiado

STARS: Strengthening training of academia in regulatory sciences and supporting regulatory scientific advic... BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-SC1-BHC-2018-2020 Lack of specific relevant know-how in regulatory science delays the development of new treatment strategies or limits the chances that promi...
2018-11-20 - 2022-06-30 | Financiado

STACCATO: European Industrial Doctorate for enhancing upstream biopharmaceutical manufacturing process develop... BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-MSCA-ITN-2018 Our ability to utilise biological systems to produce medicines has improved the quality of life for millions of EU citizens. In recent years...
2018-08-24 - 2022-12-31 | Financiado

CARAMBA: SLAMF7 CAR T cells prepared by Sleeping Beauty gene transfer for immunotherapy of multiple myeloma... BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-SC1-2016-2017 CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy....
2017-11-22 - 2023-06-30 | Financiado

CCHFVaccine: Crimean Congo Haemorrhagic Fever Vaccine BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-SC1-2016-2017 Natural epidemics and outbreaks of emerging viral epidemics are growing problems internationally. The general aim of the CCHFVaccine project...
2016-12-09 - 2024-12-31 | Financiado

VAC2VAC: Vaccine lot to Vaccine lot comparison by consistency testing. BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-JTI-IMI2-2015-03-two-stage Lot release testing of established vaccines relies on using animal models. Many of these models were developed decades ago and reflect the l...
2016-04-14 - 2022-02-28 | Financiado

CARAT: Chimeric Antigen Receptors CARs for Advanced Therapies BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-PHC-2014-2015 Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that...
2015-12-08 - 2019-12-31 | Financiado

TBVAC2020: TBVAC2020 Advancing novel and promising TB vaccine candidates from discovery to preclinical and ear... BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un H2020: H2020-PHC-2014-2015 The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccin...
2014-12-03 - 2019-06-30 | Financiado

ABIRISK: Anti Biopharmaceutical Immunization Prediction and analysis of clinical relevance to minimize the ri... BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un FP7: The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique pane...
Financiado

IFAAM: Integrated Approaches to Food Allergen and Allergy Risk Management BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un FP7: Up to 20 million European citizens suffer from food allergy. However management of both food allergy (by patients and health practitioners)...
Financiado

TARGETAMD: Transposon based targeted ex vivo gene therapy to treat age related macular degeneration AMD BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL participó en un FP7: Age-related Macular Degeneration (AMD), a neurodegenerative disease of the retina, is a major cause of blindness in elderly people. Due to t...
Financiado

PEI